Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) has been given a consensus recommendation of “Hold” by the twenty-five analysts that are currently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, sixteen have assigned a hold rating and eight have given a buy rating to the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $49.83.

A number of analysts have weighed in on the stock. Chardan Capital decreased their target price on shares of Intercept Pharmaceuticals from $58.00 to $45.00 and set a “buy” rating for the company in a research report on Monday, March 1st. Wedbush cut their price target on Intercept Pharmaceuticals from $106.00 to $88.00 and set an “outperform” rating on the stock in a report on Monday, March 8th. Needham & Company LLC cut their price target on Intercept Pharmaceuticals from $80.00 to $34.00 and set a “buy” rating on the stock in a report on Monday, March 8th. Bank of America cut Intercept Pharmaceuticals from a “neutral” rating to an “underperform” rating and cut their price target for the stock from $40.00 to $27.00 in a report on Friday, January 15th. Finally, Raymond James cut their price target on Intercept Pharmaceuticals from $60.00 to $52.00 and set an “outperform” rating on the stock in a report on Thursday, March 4th.

Shares of Intercept Pharmaceuticals stock traded down $0.83 on Thursday, hitting $19.12. The stock had a trading volume of 25,696 shares, compared to its average volume of 1,151,307. The stock has a 50 day moving average of $22.10 and a 200 day moving average of $28.45. Intercept Pharmaceuticals has a twelve month low of $18.15 and a twelve month high of $95.98. The firm has a market capitalization of $634.06 million, a P/E ratio of -2.04 and a beta of 1.85.

Intercept Pharmaceuticals (NASDAQ:ICPT) last released its quarterly earnings data on Thursday, February 25th. The biopharmaceutical company reported ($1.58) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.55) by ($0.03). The firm had revenue of $83.27 million during the quarter, compared to analyst estimates of $84.10 million. Intercept Pharmaceuticals had a negative net margin of 106.64% and a negative return on equity of 1,973.10%. On average, equities analysts anticipate that Intercept Pharmaceuticals will post -8.23 earnings per share for the current year.

In related news, Director Srinivas Akkaraju bought 147,000 shares of Intercept Pharmaceuticals stock in a transaction on Friday, March 12th. The stock was acquired at an average price of $21.29 per share, with a total value of $3,129,630.00. Following the acquisition, the director now directly owns 23,121 shares of the company’s stock, valued at $492,246.09. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. 23.70% of the stock is owned by insiders.

Hedge funds have recently bought and sold shares of the business. Credit Agricole S A boosted its position in shares of Intercept Pharmaceuticals by 37.5% during the 4th quarter. Credit Agricole S A now owns 1,650 shares of the biopharmaceutical company’s stock valued at $41,000 after acquiring an additional 450 shares during the last quarter. The Manufacturers Life Insurance Company boosted its position in shares of Intercept Pharmaceuticals by 3.1% during the 4th quarter. The Manufacturers Life Insurance Company now owns 15,801 shares of the biopharmaceutical company’s stock valued at $390,000 after acquiring an additional 473 shares during the last quarter. Rhumbline Advisers boosted its position in shares of Intercept Pharmaceuticals by 2.4% during the 4th quarter. Rhumbline Advisers now owns 32,109 shares of the biopharmaceutical company’s stock valued at $793,000 after acquiring an additional 749 shares during the last quarter. Advisory Services Network LLC boosted its position in shares of Intercept Pharmaceuticals by 537.5% during the 4th quarter. Advisory Services Network LLC now owns 1,275 shares of the biopharmaceutical company’s stock valued at $31,000 after acquiring an additional 1,075 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its position in shares of Intercept Pharmaceuticals by 0.8% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 202,701 shares of the biopharmaceutical company’s stock valued at $5,007,000 after acquiring an additional 1,631 shares during the last quarter. 85.77% of the stock is owned by institutional investors and hedge funds.

About Intercept Pharmaceuticals

Intercept Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. Its lead products candidate is the Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid in adults.

Further Reading: dividend yield calculator

Analyst Recommendations for Intercept Pharmaceuticals (NASDAQ:ICPT)

Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.